Pair page
Retatrutide with VK2735
Mechanism-tag overlap and published literature for Retatrutide and VK2735, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
incretin-peptidetriple-receptor-agonist
dual-gip-glp-1-receptor-agonistviking-therapeutics
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Retatrutide and VK2735 have published these mechanism-level observations. Not a co-administration recommendation.
Not a stack — triple GIP/GLP-1/glucagon agonist from Eli Lilly. Alternative investigational weight-loss compound with greater weight-loss ceiling in Phase 2. Do not combine.
Quick facts
Retatrutide
VK2735
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2025 | Retatrutide | Rosenstock J, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 2025. PMID: 40609566. PMID 40609566 | human trial, Phase 2 |
| 2024 | Retatrutide | Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. PMID: 38858523. PMID 38858523 | human trial, Phase 2 |
| 2023 | Retatrutide | Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315. DOI: 10.1056/NEJMoa2301972. PMID 37366315 | human trial, Phase 2 |
| 2023 | Retatrutide | Rosenstock J, Frías JP, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544.… PMID 37385280 | human trial, Phase 2 |
| 2025 | Retatrutide | Eli Lilly and Company. Topline TRIUMPH-4 readout — retatrutide in adults with obesity and knee osteoarthritis. Press release, October 2025. | human trial |
| 2023 | Retatrutide | Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131. (Comparator reference.) PMID 37952131 | human trial |
| 2022 | Retatrutide | Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PMID: 35658024. (Comparator reference.) PMID 35658024 | human trial |
| 2021 | Retatrutide | Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185. (Comparator reference.) PMID 33567185 | human trial |
| — | Retatrutide | Kjeldsen SAS, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. PMID: 41090431. PMID 41090431 | human trial |
| — | Retatrutide | ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Adult Participants Who Have Obesity or Are Overweight With Weight-Related Medical Problems (TRIUMPH-1). NCT05929066. | human trial |
| — | Retatrutide | ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Adult Participants With Obesity and Type 2 Diabetes (TRIUMPH-2). NCT05929079. | human trial |
| — | Retatrutide | ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight With Osteoarthritis of the Knee (TRIUMPH-4). NCT05931367. | human trial |
| 2024 | VK2735 | Viking Therapeutics. Corporate presentations and SEC filings, 2024–2026, detailing VK2735 Phase 2 data, oral formulation development, and anticipated Phase 3 timeline. | human trial, Phase 3 |
| 2024 | VK2735 | Viking Therapeutics. VK2735 Phase 2 (VENTURE) topline results: 13-week weight-loss data in adults with obesity. Press release and investor presentations, 2024. | human trial, Phase 2 |
| 2024 | VK2735 | Bays HE, Kelly AS, Aronne LJ, et al. Weekly subcutaneous VK2735 for weight management in adults with obesity — Phase 2 VENTURE trial. ObesityWeek 2024 / Obesity (Silver Spring). 2024. | human trial, Phase 2 |
| 2024 | VK2735 | Viking Therapeutics. Phase 1 and Phase 2 oral VK2735 program: pharmacokinetics and early weight-loss signal. 2024–2025 communications. | human trial, Phase 2 |
| 2023 | VK2735 | Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group… PMID 37385275 | human trial, Phase 2 |
| 2021 | VK2735 | Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al.; SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. PMID: 34170647. PMID 34170647 | human trial |
| — | VK2735 | ClinicalTrials.gov. A Study of VK2735 in Participants With Obesity (VENTURE). NCT05946356. | human trial |
| 2022 | VK2735 | Viking Therapeutics. Phase 1 pharmacokinetics, safety, and tolerability of subcutaneous VK2735 in healthy and obese volunteers. 2022–2023. | human trial, Phase 1 |
| 2023 | VK2735 | Wharton S, Astrup A, Endahl L, Lean MEJ, Satylganova A, Skovgaard D, Wadden TA. Oral semaglutide for the treatment of obesity. Lancet. 2023;402(10403):653-656. (Oral semaglutide class context.) | human study |
| 2018 | VK2735 | Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. PMID: 30473097. PMID 30473097 | mechanism / discovery |
| 2025 | VK2735 | World Anti-Doping Agency. 2025 WADA Prohibited List. WADA, 2025. | regulatory / registry |
Related pair pages
More research context
Frequently asked
Have Retatrutide and VK2735 been studied together?
Researchers have published mechanistic-level co-administration discussion of Retatrutide and VK2735. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Retatrutide and VK2735 share?
Retatrutide and VK2735 do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Retatrutide and VK2735?
Retatrutide: Investigational (Phase 3). VK2735: Investigational (Phase 2). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Retatrutide and VK2735?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Retatrutide profile and the VK2735 profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026